200 related articles for article (PubMed ID: 17705263)
41. Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients.
Lian M; Zhou X; Wei L; Qiu S; Zhou T; Li L; Gu X; Luo M; Zheng X
Virol J; 2007 Sep; 4():93. PubMed ID: 17892580
[TBL] [Abstract][Full Text] [Related]
42. A call for attention and trials on hepatitis B e antigen-negative, alanine aminotransferase-normal chronic hepatitis B virus infection.
Zhao H; Miao R
Hepatology; 2009 Aug; 50(2):658; author reply 658-9. PubMed ID: 19585650
[No Abstract] [Full Text] [Related]
43. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
[TBL] [Abstract][Full Text] [Related]
44. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients.
Kumar M; Chauhan R; Gupta N; Hissar S; Sakhuja P; Sarin SK
Gastroenterology; 2009 Apr; 136(4):1272-80. PubMed ID: 19208347
[TBL] [Abstract][Full Text] [Related]
45. Viremia profiles in hepatitis B virus carrier children with spontaneous e antigen seroconversion: a case of déjà vu?
Lin CL; Kao JH
Gastroenterology; 2007 Sep; 133(3):1052-3; author reply 1053-4. PubMed ID: 17854613
[No Abstract] [Full Text] [Related]
46. [Features of combined (HBV/HCV-infection) viral lesion of the liver].
Maev IV; Nikushkina IN; Samsonov AA; Aksel'rod AG
Ter Arkh; 2008; 80(2):57-61. PubMed ID: 18372598
[TBL] [Abstract][Full Text] [Related]
47. [Correlations between preS1-antigen, HBV-DNA and HBV serum markers in patients with chronic hepatitis B].
Zhou H; Jiang CW; Qian JL; Li SJ; Liang JL; Chen XF
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1184-6. PubMed ID: 18676258
[TBL] [Abstract][Full Text] [Related]
48. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.
Chu CM; Liaw YF
Gastroenterology; 2007 Nov; 133(5):1458-65. PubMed ID: 17935720
[TBL] [Abstract][Full Text] [Related]
49. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia.
Elkady A; Tanaka Y; Kurbanov F; Oynsuren T; Mizokami M
J Gastroenterol Hepatol; 2008 Mar; 23(3):474-81. PubMed ID: 18318825
[TBL] [Abstract][Full Text] [Related]
50. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
51. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
[TBL] [Abstract][Full Text] [Related]
52. Adenosine deaminase activity in serum of patients with hepatitis -- a useful tool in monitoring clinical status.
Kaya S; Cetin ES; Aridogan BC; Arikan S; Demirci M
J Microbiol Immunol Infect; 2007 Aug; 40(4):288-92. PubMed ID: 17712462
[TBL] [Abstract][Full Text] [Related]
53. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus.
Chu CM; Liaw YF
Am J Gastroenterol; 2009 Jul; 104(7):1693-9. PubMed ID: 19455130
[TBL] [Abstract][Full Text] [Related]
54. Presence and persistence of Australia antigen among drug addicts.
Nordenfelt E; Kaij K; Ursing B
Vox Sang; 1970; 19(3):371-8. PubMed ID: 4100647
[No Abstract] [Full Text] [Related]
55. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus.
Kiesslich D; Crispim MA; Santos C; Ferreira Fde L; Fraiji NA; Komninakis SV; Diaz RS
J Infect Dis; 2009 Jun; 199(11):1608-11. PubMed ID: 19388852
[TBL] [Abstract][Full Text] [Related]
56. Occult hepatitis B virus infection in HIV-infected Lebanese patients with isolated antibodies to hepatitis B core antigen.
Ramia S; Mokhbat J; Ramlawi F; El-Zaatari M
Int J STD AIDS; 2008 Mar; 19(3):197-9. PubMed ID: 18397562
[TBL] [Abstract][Full Text] [Related]
57. Clinical significance of hepatitis B surface antigen in cord blood of hepatitis B e-antigen-negative chronic hepatitis B virus-infected mothers.
Elefsiniotis IS; Papadakis M; Vlahos G; Daskalakis G; Saroglou G; Antsaklis A
Intervirology; 2009; 52(3):132-4. PubMed ID: 19468236
[TBL] [Abstract][Full Text] [Related]
58. Antiviral therapy in HBe-Ag-positive hepatitis B with normal aminotransferase levels.
Geier A; Dietrich CG; Gartung C
Hepatology; 2003 Mar; 37(3):712-3; author reply 713. PubMed ID: 12601370
[No Abstract] [Full Text] [Related]
59. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
60. Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: story beyond A1762T/G1764A mutations.
Liu CJ; Kao JH
J Gastroenterol Hepatol; 2008 Mar; 23(3):347-50. PubMed ID: 18318819
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
